FINWIRES · TerminalLIVE
FINWIRES

$ROIV

5 stories mentioning ROIV

Every FINWIRES story that references ROIV, newest first.

Insider Trading

Roivant Sciences Insider Sold Shares Worth $6,054,000, According to a Recent SEC Filing

Eric Venker, President & Immunovant Chief Executive Officer, on May 20, 2026, sold 200,000 shares in Roivant Sciences (ROIV) for $6,054,000. Following the Form 4 filing with the SEC, Venker has control over a total of 1,613,063 common shares of the company, with 1,613,063 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1635088/000163508826000065/xslF345X05/wk-form4_1779488744.xml

$ROIV
Sectors

Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday

Healthcare stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) advancing by 0.8%.Roivant Sciences (ROIV) stock was up nearly 6% after the company reported that it swung to a fiscal Q4 net income.ImmunityBio's (IBRX) supplemental biologics license application for Anktiva in combination with Bacillus Calmette-Guerin in patients with bladder cancer with papillary disease has been accepted for review by the US Food and Drug Administration, the company said. ImmunityBio shares were 8% higher pre-bell.Natera (NTRA) stock was up more than 2% after the company said the trial evaluating its Fetal Focus single-gene noninvasive prenatal test has enrolled more than 2,000 patients, more than doubling enrollment over the past year.

$IBB$IBRX$NTRA$ROIV$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) advancing by 0.6%.Roivant Sciences (ROIV) stock was up more than 8% after the company reported that it swung to a fiscal Q4 net income.

$ROIV
Insider Trading

Roivant Sciences Insider Sold Shares Worth $5,918,000, According to a Recent SEC Filing

Eric Venker, President & Immunovant Chief Executive Officer, on April 20, 2026, sold 200,000 shares in Roivant Sciences (ROIV) for $5,918,000. Following the Form 4 filing with the SEC, Venker has control over a total of 1,647,546 common shares of the company, with 1,647,546 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1635088/000163508826000044/xslF345X05/wk-form4_1776896865.xml

$ROIV
Insider Trading

Roivant Sciences Insider Sold Shares Worth $8,449,810, According to a Recent SEC Filing

Matthew Gline, Director, Chief Executive Officer, on April 16, 2026, sold 289,774 shares in Roivant Sciences (ROIV) for $8,449,810. Following the Form 4 filing with the SEC, Gline has control over a total of 16,736,116 common shares of the company, with 16,736,116 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1635088/000163508826000038/xslF345X05/wk-form4_1776724041.xml

$ROIV